Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 40
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Actualización sobre el tratamiento de la tuberculosis

  • Martínez-Campreciós, Joan|||0000-0002-8899-8447
  • Espinosa-Pereiro, Juan|||0000-0002-7238-8337
  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
Tuberculosis (TB) affects more than 10 million people each year. We have contested this burden with a paradoxically slow development of treatments, as compared to other infectious diseases. This review aims to update health care professionals on the last developments for the management of TB. The combination of drugs established more than 40 years ago is still adequate to cure most people affected by TB. However, with the generalisation of regimens based on rifampicin and isoniazid for (only) 6 months, resistance emerged. Resistant cases needed long treatments based on injectable drugs. Now, after an exciting decade of research, we can treat resistant TB with oral regimens based on bedaquiline, nitroimidazoles, and linezolid for (only) 6 months, and we may soon break the 6-month barrier for treatment duration. However, these improvements are not enough to end TB without an engagement of people affected and their communities to achieve adherence to treatment, transmission control, and improve socioeconomic determinants of health.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Safety, Efficacy and Pharmacokinetics of daily optimised doses of Rifampicin for the Treatment of Tuberculosis: A Systematic Review and Bayesian Network Meta-Analysis

  • Espinosa-Pereiro, Juan|||0000-0002-7238-8337
  • Aguiar, Ana|||0000-0001-7841-7410
  • Nara, Eva
  • Medina, Angelica
  • Molinas, Gladys
  • Tavares, Margarida|||0000-0003-4518-2197
  • Tórtola Fernández, María Teresa|||0000-0002-9188-298X
  • Ghimire, Samiksha|||0000-0002-6028-1460
  • Alfenaar, Jan-Willem C.
  • Sturkenboom, Marieke G. G.|||0000-0002-3420-0591
  • Magis-Escurra, Cecile|||0000-0001-8424-9425
  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
  • Barros, Henrique
  • Duarte, Raquel
Background: Higher than standard doses of rifampicin could improve the treatment outcome of drug-susceptible tuberculosis without compromising the safety of patients. Methods: We performed a systematic review of prospective clinical studies including adults with pulmonary and extrapulmonary TB receiving rifampicin doses above 10mg/kg/day. We extracted the data on overall adverse events (AE), hepatic AE, sputum culture conversion (SCC) at week 8, recurrence, mortality, and pharmacokinetics. We performed a Bayesian network meta-analysis (NMA) using a random-effects model. Results: In 19 studies, 2033 out of 3654 participants received rifampicin doses higher than 10mg/kg/day. The NMA showed an increased risk of overall and hepatic AE for the 40mg/kg/day dose (RR 4.8, 95% CrI 1.1; 25, and 15.00, 95% CrI 1.1; 58.0, respectively), but no other doses, including 50mg/kg/day showed such an increase. Increasing doses improved sputum culture conversion at week 8 (RR 1.3, 95% CrI 1.1; 1.7 for SCC with 35mg/kg/day). Conclusion: Optimal doses of rifampicin may be between 25 and 35mg/kg/day, but should be tailored at the individual or, at least, at the population level.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Efficacy of Tocilizumab for hospitalized patients with COVID-19 pneumonia and high IL-6 levels: A randomized controlled trial

  • Sellarès-Nadal, Júlia|||0000-0002-0209-6494
  • Espinosa-Pereiro, Juan|||0000-0002-7238-8337
  • Burgos, Joaquín|||0000-0001-8445-3047
  • Falcó, Vicenç|||0000-0001-9626-0023
  • Guillén-Del-Castillo, Alfredo|||0000-0003-0626-507X
  • Augustin Recio, Salvador|||0000-0002-3515-9033
  • Bañares-Sánchez, Joan
  • Prio-Ruatg, Alba
  • Martínez-Valle, Ferran
  • Kirkegaard, Cristina|||0000-0001-9035-1450
  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
Background: The objective of this clinical trial is to evaluate the efficacy and safety of IL-6 driven personalized treatment strategy with tocilizumab in patients with severe COVID-19 pneumonia. Trial design: Randomized, controlled, open-label, single-center trial of a tocilizumab treatment strategy in adult patients hospitalized with severe COVID-19 pneumonia and IL-6 serum levels.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Validation of a pregnancy-adapted Mediterranean Diet Adherence Screener (preg-MEDAS), a validation study nested in the Improving Mothers for a better PrenAtal Care Trial BarCeloNa (IMPACT BCN) trial

  • Castro Barquero, Sara|||0000-0002-6876-5443
  • Crovetto, Francesca|||0000-0003-0140-7411
  • Estruch, Ramón|||0000-0003-1260-4445
  • Ruiz-León, Ana María
  • Larroya, Marta|||0000-0001-7929-6630
  • Sacanella, Emilio|||0000-0001-8018-1523
  • Casanovas-Garriga, Francesc
  • Casas, Irene
  • Nakaki, Ayako|||0000-0002-4395-3878
  • Youssef, Lina|||0000-0002-0554-5507
  • Trejo-Domínguez, Alejandra|||0000-0002-5448-275X
  • Benitez, Leticia|||0000-0002-4950-036X
  • Genero, Mariona
  • Vieta, Eduard|||0000-0002-0548-0053
  • Gratacós, Eduard|||0000-0002-7405-7224
  • Crispi, Fatima|||0000-0002-7422-5240
  • Casas, Rosa|||0000-0002-0211-9166
Background: Non-time-consuming and easy-to-administer dietary assessment tools specific for pregnancy are needed. Objectives: The aim of this validation study nested in the IMPACT BCN (Improving Mothers for a better PrenAtal Care Trial BarCeloNa) trial is to determine the concurrent validity of the 17-item pregnancy-adapted Mediterranean diet score (preg-MEDAS) and to analyze whether changes in the preg-MEDAS score were associated with maternal favorable dietary and cardiometabolic changes after 3 mo of intervention in pregnant women. Methods: Dietary data was collected in 812 participants using the preg-MEDAS and a 151-item validated food frequency questionnaire (FFQ) at baseline (19-23 wk gestation) and final visit (31-34 wk gestation). Concurrent preg-MEDAS validity was evaluated by Pearson and intraclass correlation coefficients, κ statistic, and Bland-Altman methods. Results: The preg-MEDAS had a good correlation with the FFQ (r = 0.76 and intraclass correlation coefficient 0.75). The agreement of each of the preg-MEDAS items ranged from 40.9% to 93.8% with a substantial agreement mean concordance (κ = 0.61). A 2-point increase in preg-MEDAS was associated with a decrease in maternal mean and systolic blood pressure (β: -0.51 mmHg; 95% confidence interval [CI]: -0.97, -0.04 mmHg and -0.87 mmHg; 95% CI: -1.48, -0.26 mmHg, respectively). Conclusions: The preg-MEDAS displays good validity for assessing adherence to the Mediterranean diet, allowing detection of dietary changes over time. In addition, changes observed in preg-MEDAS are significantly associated with a decrease in maternal blood pressure. Therefore, we propose preg-MEDAS as a rapid and simple dietary assessment tool during pregnancy. This trial was registered at clinicaltrials.gov as NCT03166332.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Effect of Mediterranean diet or mindfulness-based stress reduction during pregnancy on placental volume and perfusion, A subanalysis of the IMPACT BCN randomized clinical trial

  • Nakaki, Ayako|||0000-0002-4395-3878
  • Denaro, Eugenio
  • Crimella, Maddalena
  • Castellani, Roberta
  • Vellvé, Kilian|||0000-0002-2376-7664
  • Izquierdo, Nora
  • Basso, Annachiara
  • Paules, Cristina|||0000-0001-6795-0367
  • Casas, Rosa|||0000-0002-0211-9166
  • Benitez, Leticia|||0000-0002-4950-036X
  • Casas, Irene
  • Larroya, Marta|||0000-0001-7929-6630
  • Genero, Mariona
  • Castro Barquero, Sara|||0000-0002-6876-5443
  • Gomez-Gomez, A|||0000-0001-8172-1827
  • Pozo, Oscar J|||0000-0002-1735-9728
  • Vieta, Eduard|||0000-0002-0548-0053
  • Estruch, Ramón|||0000-0003-1260-4445
  • Nadal, Alfons
  • Gratacós, Eduard|||0000-0002-7405-7224
  • Crovetto, Francesca|||0000-0003-0140-7411
  • Crispi, Fatima|||0000-0002-7422-5240
  • Youssef, Lina|||0000-0002-0554-5507
Introduction: The IMPACT BCN trial-a parallel-group randomized clinical trial where 1221 pregnant women at high risk for small-for-gestational age (SGA) newborns were randomly allocated at 19- to 23-week gestation into three groups: Mediterranean diet, Mindfulness-based Stress reduction or non-intervention-has demonstrated a positive effect of Mediterranean diet and Stress reduction in the prevention of SGA. However, the mechanism of action of these interventions remains still unclear. The aim of this study is to investigate the effect of Mediterranean diet and Stress reduction on placental volume and perfusion. Material and Methods: Participants in the Mediterranean diet group received monthly individual and group educational sessions, and free provision of extra-virgin olive oil and walnuts. Women in the Stress reduction group underwent an 8-week Stress reduction program adapted for pregnancy, consisting of weekly 2.5-h and one full-day sessions. Non-intervention group was based on usual care. Placental volume and perfusion were assessed in a subgroup of randomly selected women (n = 165) using magnetic resonance (MR) at 36-week gestation. Small placental volume was defined as MR estimated volume <10th centile. Perfusion was assessed by intravoxel incoherent motion. Results: While mean MR placental volume was similar among the study groups, both interventions were associated with a lower prevalence of small placental volume (3.9% Mediterranean diet and 5% stress reduction vs. 17% non-intervention; p = 0.03 and p = 0.04, respectively). Logistic regression showed that small placental volume was significantly associated with higher risk of SGA in both study groups (OR 7.48 [1.99-28.09] in Mediterranean diet and 20.44 [5.13-81.4] in Stress reduction). Mediation analysis showed that the effect of Mediterranean diet on SGA can be decomposed by a direct effect and an indirect effect (56.6%) mediated by a small placental volume. Similarly, the effect of Stress reduction on SGA is partially mediated (45.3%) by a small placental volume. Results on placental intravoxel incoherent motion perfusion fraction and diffusion coefficient were similar among the study groups. Conclusions: Structured interventions during pregnancy based on Mediterranean diet or Stress reduction are associated with a lower proportion of small placentas, which is consistent with the previously observed beneficial effects of these interventions on fetal growth.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Mediterranean Diet in Pregnancy, Implications for Maternal Brain Morphometry in a Secondary Analysis of the IMPACT BCN Randomized Clinical Trial

  • Nakaki, Ayako|||0000-0002-4395-3878
  • Gomez, Yvan|||0000-0003-0794-7750
  • Castro Barquero, Sara|||0000-0002-6876-5443
  • Conti, Allegra|||0000-0003-4210-5065
  • Vellvé, Kilian|||0000-0002-2376-7664
  • Casas, Irene
  • Genero, Mariona
  • Youssef, Lina|||0000-0002-0554-5507
  • Segalés Tañà, Laura|||0000-0002-8583-8835
  • Benitez, Leticia|||0000-0002-4950-036X
  • Casas, Rosa|||0000-0002-0211-9166
  • Vieta, Eduard|||0000-0002-0548-0053
  • Bargalló, Núria|||0000-0001-6284-5402
  • Toschi, Nicola
  • Estruch, Ramón|||0000-0003-1260-4445
  • Crispi, Fatima|||0000-0002-7422-5240
  • Gratacós, Eduard|||0000-0002-7405-7224
  • Crovetto, Francesca|||0000-0003-0140-7411
INTRODUCTION: A Mediterranean diet has positive effects on the brain in mid-older adults; however, there is scarce information on pregnant individuals. We aimed to evaluate the effect of a structured Mediterranean diet intervention on the cortical structure of the maternal brain during pregnancy. METHODS: This study was a secondary analysis of the IMPACT BCN, a randomized clinical trial with 1221 high-risk pregnant women randomly allocated into three groups at 19-23 weeks of gestation: Mediterranean diet intervention, a mindfulness-based stress reduction program, or usual care. Maternal brain magnetic resonance imaging was performed during the third trimester of pregnancy in a random subgroup of participants. For this study, data from the Mediterranean diet and usual groups were analyzed. Maternal dietary intake, adherence to the Mediterranean diet and metabolite biomarkers were evaluated using a food frequency questionnaire, a 17-item dietary screener and plasma/urine samples, respectively. RESULTS: The cluster-wise analysis showed that the Mediterranean diet group participants (n = 34) had significantly larger surface areas in the right precuneus (90%CI: <0.0001-0.0004, p < 0.001) and left superior parietal (90%CI: 0.026-0.033, p = 0.03) lobules compared to the usual care group participants (n = 37). A larger right precuneus area was associated with high improvements in adherence to the Mediterranean diet, a high intake of walnuts and high concentrations of urinary hydroxytyrosol. A larger left superior parietal area was associated with a high intake of walnuts and high concentrations of urinary hydroxytyrosol. CONCLUSIONS: The promotion of a Mediterranean diet during pregnancy has a significant effect on maternal brain structure.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Global and Sex-Stratified Genome-Wide Association Study of Long COVID Based on Patient-Driven Symptom Recall

  • Polo-Alonso, Sara
  • Hernáez, Álvaro|||0000-0001-8593-1477
  • Degano, Irene R.|||0000-0003-1914-6934
  • Martí-Lluch, Ruth|||0000-0002-7320-9521
  • Pinsach-Abuin, Mel Lina
  • Elosua, Roberto|||0000-0001-8235-0095
  • Subirana, Isaac|||0000-0003-1676-0197
  • Puigmulé, Marta
  • Pérez, Alexandra|||0000-0001-5344-6573
  • Cruz, Raquel|||0000-0002-6964-8898
  • Diz-de Almeida, Silvia|||0000-0003-2813-8928
  • Puigdecant, Eulàlia
  • Selga, Elisabet|||0000-0002-4290-8370
  • Nogués Solán, Xavier|||0000-0002-5537-1859
  • Masclans, Joan R.|||0000-0002-0809-6823
  • Güerri-Fernández, Robert|||0000-0002-9794-9161
  • Cubero-Gallego, Hector|||0000-0001-9740-827X
  • Tizón-Marcos, Helena|||0000-0001-7942-9413
  • Vaquerizo, Beatriz|||0000-0002-1428-3596
  • Brugada, Ramon|||0000-0001-6607-3032
  • Ramos, Rafel|||0000-0001-7970-5537
  • Camps-Vilaró, Anna|||0000-0001-9644-8421
  • Marrugat, Jaume|||0000-0003-3320-554X
We aimed to explore the global and sex-specific genetic variants associated with long COVID, as defined by patient-driven symptom recall. A 1-year cohort study of 2411 COVID-19 patients collected long COVID symptoms with an open-ended, non-directed questionnaire, and long COVID incidence was determined according to the World Health Organization definition. Global and sex-stratified genome-wide association analyses were conducted by logistic regression models adjusted for age, sex (in the global analysis), and the first 10 principal components. We assessed sex-variant interactions and performed gene-based analyses, gene mapping, and gene-set enrichment analyses. When comparing the 1392 long COVID cases with the non-cases, we identified 23 lead variants from suggestive signals: 13 from the global analysis, 5 from females, and 5 from males. Five variants showed a significant interaction with sex (two in females, three in males). We mapped 15 protein-coding genes related to diseases of the immune and nervous systems and tumoral processes. Notably, CD5 and VPS37C, linked to immune function, were significantly associated with long COVID in men. Our results suggest that persistent immune dysregulation may be involved in the development of precisely defined long COVID.
Repisalud
Publication Artículo científico (JournalArticle)

Substitutions in position 222 of haemagglutinin of pandemic influenza A (H1N1) 2009 viruses in Spain

  • Ledesma, Juan
  • Pozo Sanchez, Francisco
  • Pérez-Ruiz, Mercedes
  • Navarro, José María
  • Piñeiro, Luis
  • Montes, Milagros
  • Pérez Castro, Sonia
  • Suárez Fernández, Jonathan
  • García Costa, Juan
  • Fernández, Mirian
  • Galán, Juan Carlos
  • Cuevas, Maria Teresa
  • Casas Flecha, Inmaculada
  • Perez-Breña, Pilar
  • Spanish Influenza Surveillance System (SISS)
  • Jimenez-Jorge, Silvia
Background: A change of aspartic acid (D) to glycine (G) at position 222 in the haemagglutinin (HA) protein of pandemic influenza A (H1N1) 2009 viruses was described in Norway on November 2009 with considerable frequency in fatal and severe cases. This change was detected in other countries and was related only with severe disease. Other substitutions to glutamic acid (E) or asparagine (N) at position 222 were detected among pandemic viruses but it is unclear what implications might have in terms of severity. Objectives: To analyse the appearance of amino acid substitutions at position 222 in the HA protein of circulating viruses in Spain and to determine their relationships with the disease symptoms observed. Study design: Pandemic influenza A (H1N1) 2009 viruses detected in respiratory samples of 273 severe and 533 non-severe cases from different Spanish regions were selected for sequencing of a partial segment of HA1 subunit and studied to monitor substitutions at position 222. Results: D222G substitution was only detected in viruses from 14 severe cases (5.12%). D222E was found in viruses from 47 severe (17.21%) and from 52 non-severe cases (9.75%). D222N occurred in viruses from 3 additional severe cases (0.37%). Conclusion: Appearance of D222G and D222E substitution in HA of pandemic influenza A (H1N1) viruses circulating in Spain might be related with severe respiratory disease.
Repisalud
Publication Artículo científico (JournalArticle)

Genetic diversity of influenza A(H1N1)2009 virus circulating during the season 2010-2011 in Spain

  • Ledesma, Juan
  • Pozo Sanchez, Francisco
  • Reina, Gabriel
  • Blasco, Miriam
  • Rodríguez, Guadalupe
  • Montes, Milagrosa
  • López-Miragaya, Isabel
  • Salvador, Carmen
  • Reina, Jordi
  • Ortíz de Lejarazu, Raúl
  • Egido, Pilar
  • López Barba, José
  • Delgado-Sanz, Concepcion
  • Cuevas, Maria Teresa
  • Casas Flecha, Inmaculada
  • Spanish Influenza Surveillance System (SISS)
  • Larrauri, Amparo
  • Jimenez-Jorge, Silvia
Background: Genetic diversity of influenza A(H1N1)2009 viruses has been reported since the pandemic virus emerged in April 2009. Different genetic clades have been identified and defined based on amino acid substitutions found in the haemagglutinin (HA) protein sequences. In Spain, circulating influenza viruses are monitored each season by the regional laboratories enrolled in the Spanish Influenza Surveillance System (SISS). The analysis of the HA gene sequence helps to detect the genetic diversity and viral evolution. Objectives: To perform an analysis of the genetic diversity of influenza A(H1N1)2009 viruses circulating in Spain during the season 2010-2011 based on analysis of the HA sequence gene. Study design: Phylogenetic analysis based on the HA1 subunit of the haemagglutinin gene was carried out on 220 influenza A(H1N1)2009 viruses circulating during the season 2010-2011. Results: Six different genetic groups were identified among circulating A(H1N1)2009 viruses, five of them were previously reported during season 2010-2011. A new group, characterized by E172K and K308E changes and a proline at position 83, was observed in 12.27% of the Spanish viruses. Conclusion: Co-circulation of six different genetic groups of influenza A(H1N1)2009 viruses was identified in Spain during the season 2010-2011. Nevertheless, at this stage, none of the groups identified to date have resulted in significant antigenic changes according to data collected by World Health Organization Collaborating Centres for influenza surveillance.
Repisalud
Publication Artículo científico (JournalArticle)

Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia

  • Vega-Garcia, Nerea
  • Benito, Rocío
  • Esperanza-Cebollada, Elena
  • Llop, Marta
  • Robledo, Cristina
  • Vicente-Garcés, Clara
  • Alonso, Javier
  • Barragan, Eva
  • Fernández, Guerau
  • Hernández-Sánchez, Jesús M
  • Martín-Izquierdo, Marta
  • Maynou, Joan
  • Minguela, Alfredo
  • Montaño, Adrián
  • Ortega, Margarita
  • Torrebadell, Montserrat
  • Cervera, José
  • Sánchez, Joaquín
  • Jiménez-Velasco, Antonio
  • Riesco, Susana
  • Hernández-Rivas, Jesús M
  • Lassaletta, Álvaro
  • Fernández, José María
  • Rives, Susana
  • Dapena, José Luis
  • Ramírez, Manuel
  • Camós, Mireia
  • Spanish Society of Pediatric Hematology and Oncology (SEHOP). Group of Leukemia
The development of Next-Generation Sequencing (NGS) has provided useful diagnostic, prognostic, and therapeutic strategies for individualized management of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients. Consequently, NGS is rapidly being established in clinical practice. However, the technology's complexity, bioinformatics analysis, and the different available options difficult a broad consensus between different laboratories in its daily routine introduction. This collaborative study among Spanish centers was aimed to assess the feasibility, pros, and cons of our customized panel and other commercial alternatives of NGS-targeted approaches. The custom panel was tested in three different sequencing centers. We used the same samples to assess other commercial panels (OncomineTM Childhood Cancer Research Assay; Archer®FusionPlex® ALL, and Human Comprehensive Cancer Panel GeneRead Panel v2®). Overall, the panels showed a good performance in different centers and platforms, but each NGS approach presented some issues, as well as pros and cons. Moreover, a previous consensus on the analysis and reporting following international guidelines would be preferable to improve the concordance in results among centers. Our study shows the challenges posed by NGS methodology and the need to consider several aspects of the chosen NGS-targeted approach and reach a consensus before implementing it in daily practice.
Repisalud
Publication Artículo científico (JournalArticle)

The specific seroreactivity to ∆Np73 isoforms shows higher diagnostic ability in colorectal cancer patients than the canonical p73 protein

  • Garranzo-Asensio, Maria
  • Guzmán-Aránguez, Ana
  • Poves, Carmen
  • Fernández-Aceñero, María Jesús
  • Montero-Calle, Ana Maria
  • Cerón, María-Ángeles
  • Fernandez-Diez, Servando
  • Rodríguez, Nuria
  • Gómez de Cedrón, Marta
  • Ramírez de Molina, Ana
  • Domínguez, Gemma
  • Barderas Manchado, Rodrigo
The p53-family is tightly regulated at transcriptional level. Due to alternative splicing, up to 40 different theoretical proteoforms have been described for p73 and at least 20 and 10 for p53 and p63, respectively. However, only the canonical proteins have been evaluated as autoantibody targets in cancer patients for diagnosis. In this study, we have cloned and expressed in vitro the most upregulated proteoforms of p73, ΔNp73α and ΔNp73β, for the analysis of their seroreactivity by a developed luminescence based immunoassay test using 145 individual plasma from colorectal cancer, premalignant individuals and healthy controls. ∆Np73α seroreactivity showed the highest diagnostic ability to discriminate between groups. The combination of ∆Np73α, ∆Np73β and p73 proteoforms seroreactivity were able to improve their individual diagnostic ability. Competitive inhibition experiments further demonstrated the presence of unique specific epitopes in ΔNp73 isoforms not present in p73, with several colorectal patients showing unique and specific seroreactivity to the ΔNp73 proteoforms. Overall, we have increased the complexity of the humoral immune response to the p53-family in cancer patients, showing that the proteoforms derived from the alternative splicing of p73 possess a higher diagnostic ability than the canonical protein, which might be extensive for p53 and p63 proteins.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Prediction of Left Ventricular Thrombus After Myocardial Infarction: A Cardiac Magnetic Resonance-Based Prospective Registry

  • Bertolín-Boronat, Carlos
  • Marcos-Garcés, Víctor
  • Merenciano-Gonzalez, Héctor
  • Perez, Nerea
  • Pérez del Villar, Candelas
  • Lopez-Lereu, Maria P.
  • Monmeneu, Jose V.
  • Herrera Flores, Cristian
  • Domenech-Ximenos, Blanca
  • Lopez Fornas, F
  • Rios-Navarro, César
  • De Dios, Elena
  • Ortiz-Perez, Jose T.
  • Gavara-Doñate, Josep|||0000-0002-3483-7066
  • Moratal, David|||0000-0002-2825-3646
[EN] Background: Left ventricular thrombus (LVTh) is a severe complication after ST-segment elevation myocardial infarction (STEMI). Objectives: We aim to predict LVTh occurrence by cardiac magnetic resonance (CMR) using clinical, echocardiographic, and electrocardiographic (ECG) variables readily available at admission. Methods: We included 590 reperfused STEMI patients who underwent early (1-week) and/or late (6-month) CMR in our institution. Baseline clinical, echocardiographic (left ventricular ejection fraction -LVEF-) and ECG data (summatory of ST-segment elevation -sum-STE- and Q-wave and residual ST-elevation >1 mm -Q-STE-) during admission were registered. Multivariate binary logistic regression models and receiver operating characteristic curves were computed for LVTh prediction. Results: LVTh was detected by CMR in 43 (7.3 %) patients and was predicted by previous chronic coronary syndrome (CCS, HR 4.74 [1.82-12.35], p = 0.001), anterior STEMI (HR 10.93 [2.47-48.31], p = 0.002), LVEF (HR 0.96 [0.93-0.99] per %, p = 0.008), maximum sum-STE (HR 1.04 [1.01-1.07] per mm, p = 0.04), and Q-STE (HR 1.31 [1.08-1.6] per lead, p = 0.008). High-risk patients with both major (anterior STEMI and Q-STE in >= 1 leads) and 1-3 minor (CCS, maximum sum-STE >10 mm, LVEF <50%) factors showed the highest LVTh risk (19.6 % within 6 months). The model showed excellent discrimination ability (area under the curve=0.85 [0.81-0.9], p < 0.001). Simplified 4-variable (excluding sum-STE) and 3-variable (also excluding CCS) risk scores showed similar discrimination ability and were externally validated. Conclusions: LVTh within 6 months post-STEMI can be predicted using pre-discharge clinical (anterior infarction and CCS), echocardiographic (LVEF), and ECG (sum-STE and Q-STE) data. Our results can help select patients who should undergo CMR after STEMI for LVTh detection., This work was supported by Instituto de Salud Carlos III, Fondos Europeos de Desarrollo Regional FEDER and Fondo Social Europeo Plus (FSE+) (grant numbers PI20/00637, PI23/01150, CIBERCV16/11/00486, CIBERCV16/11/00420, CIBERCV16/11/00479, CIBERCV16/11/00292 and postgraduate contracts CM21/00175, CM23/00246 and CM23/00238) and by Conselleria de Innovacion, Universidades, Ciencia y Sociedad Digital of the Generalitat Valenciana (PROMETEO/2021/008).Dr. Marcos-Garces acknowledges funding from the Instituto de Salud Carlos III and co-funding from Fondo Social Europeo Plus (FSE+) (grant JR23/00032), as well as a GE 2023 grant from the Conselleria de Innovacion, Universidades, Ciencia y Sociedad Digital of the Generalitat Valenciana (CIGE/2022/26).Dr. Gavara has received financial support from the Agencia Estatal de Investigacion (grant FJC2020-043981-I/AEI/10.13039/501100011033).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Depression, Anxiety, and Quality of Life in a Cardiac Rehabilitation Program Without Dedicated Mental Health Resources Post-Myocardial Infarction

  • C Bertolin-Boronat
  • Marcos-Garcés, Víctor
  • Merenciano-Gonzalez H
  • Martínez Mas, Maria Luz
  • Climent Alberola, Josefa Inés
  • Pérez, Nerea
  • Lopez Bueno, Laura
  • Esteban Argente, Maria Concepcion
  • Valls Reig, Maria
  • Arizon Benito, Ana
  • Paya Rubio, Alfonso
  • Rios-Navarro, César
  • De Dios, Elena
  • Gavara, Jose
  • Jiménez-Navarro, Manuel F.
[EN] Anxiety and depression are common after a myocardial infarction (MI), so psychological and psychiatric mental health (MH) interventions are recommended during Cardiac Rehabilitation Programs (CRP). We aim to evaluate anxiety and depression symptoms and quality of life in MI sufferers followed in a CRP without dedicated MH resources. We prospectively included 164 MI patients in our CRP without dedicated MH resources. Patient Health Questionnaire 2-item (PHQ-2) and Generalized Anxiety Disorder 2-item (GAD-2) questionnaires for depression and anxiety screening (altered if >= 3 points) and the 36-Item Short Form Survey Instrument (SF-36) to analyze four MH components and Mental Component Summary (MCS) were assessed at the beginning and after CRP. The mean age was 61.35 +/- 10.76 years, and most patients were male (86.6%). A significant improvement in SF-36 mental components (from +5.94 +/- 27.98 to +8.31 +/- 25 points, p < 0.001) and SF-36-MCS (+1.85 +/- 10.23 points, p = 0.02) was noted, as well as a reduction in depression and anxiety symptoms in PHQ-2 and GAD-2 (p < 0.001). However, 33 (20.1%) patients showed a positive screening for depression and/or anxiety at the end of the program. These patients were younger (56.6 +/- 8.05 vs. 62.55 +/- 11.05 years, p = 0.004) and showed significantly worse initial scores of SF-36 mental components, PHQ-2, and GAD-2 (p < 0.001). We conclude that a Phase 2 CRP without dedicated MH resources can achieve significant improvements in MH well-being after MI. However, one-fifth of the population had substantial depression and/or anxiety symptoms at the end of the program. This subset, characterized by worse initial MH scores, may benefit from specific MH interventions during CRP., This research was funded by Instituto de Salud Carlos III, Fondos Europeos de Desarrollo Regional FEDER and Fondo Social Europeo Plus (FSE+) (grant numbers PI20/00637, PI23/01150, CIBERCV16/11/00486, CIBERCV16/11/00420, CIBERCV16/11/00479 and postgraduate contracts CM21/00175 and CM23/00246) and by Conselleria de Educacion of the Generalitat Valenciana (PROMETEO/2021/008). Dr. Marcos-Garces acknowledges funding from the Instituto de Salud Carlos III and co-funding from Fondo Social Europeo Plus (FSE+) (grant JR23/00032). Drs. Rios-Navarro and Gavara acknowledge funding from the Conselleria de Educacion-Generalitat Valenciana and co-funding from Fondo Social Europeo Plus (grant numbers CIAPOS/2023/247, and CIAPOS2023/248).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Left ventricular remodeling after myocardial infarction pathophysiology, diagnostic approach and management during Cardiac Rehabilitation

  • Marcos-Garcés, Víctor
  • Bertolín-Boronat, Carlos
  • Merenciano-Gonzalez, Héctor
  • Martínez Mas, Maria Luz
  • Climent Alberola, Josefa Inés
  • Lopez Bueno, Laura
  • Paya Rubio, Alfonso
  • Pérez-Solé, Nerea
  • Rios-Navarro, César
  • De Dios, Elena
  • Rodríguez-Palomares, Jose F.
  • Ortiz-Perez, Jose T.
  • Sanchis, Juan
  • Gavara-Doñate, Josep|||0000-0002-3483-7066
  • Moratal, David|||0000-0002-2825-3646
[EN] Despite the improvement in prognosis in patients with acute myocardial infarction (AMI), a significant proportion of survivors still experience heart failure (HF)-related adverse outcomes. Adverse left ventricular remodeling (LVR), which refers to a progressive dilation of left ventricular (LV) end-diastolic and end-systolic volumes, usually accompanied by a deterioration in LV systolic function, occurs frequently and underlies most cases of HF development after AMI. In this review, we discuss the current definitions of post-AMI LVR, the most appropriate imaging modalities for its detection, and the pathophysiological mechanisms by which Cardiac Rehabilitation (CR) can improve LVR-including exercise interventions, cardiovascular risk factors control, and pharmacological therapy optimization. Finally, we provide up-to-date recommendations for the follow-up and management of LVR in post-AMI patients enrolled in CR and outline future prospects on this topic., This research was funded by the Instituto de Salud Carlos III, Fondos Europeos de Desarrollo Regional FEDER and Fondo Social Europeo Plus (FSE+) (grant numbers PI23/01150, PI15/00531, CB16/11/00486, CB16/11/00420, and CB16/11/00479 and postgraduate contracts CM21/00175 and CM23/00246) and by Conselleria de Educacion of the Generalitat Valenciana (CIPROM/2024/028). Dr. Marcos-Garces acknowledges funding from the Instituto de Salud Carlos III and co-funding from Fondo Social Europeo Plus (FSE+) (grant JR23/00032), as well as a GE 2023 grant from the Conselleria de Innovacion, Universidades, Ciencia y Sociedad Digital of the Generalitat Valenciana (CIGE/2022/26). Dr. Ortiz-Perez acknowledges partial financial support from Fundacio La Marato de TV3 (grant number 20153030-31-32), Siemens Healthcare, and La Caixa Banking Foundation (HR17-00527). Dr. Gavara acknowledges funding from the Conselleria de Educacion-Generalitat Valenciana and co-funding from Fondo Social Europeo Plus (grant number CIAPOS/2023/247). Dr. Moratal has received financial support from the Conselleria d'Educacio, Investigacio, Cultura i Esport, Generalitat Valenciana (grants AEST/2019/037 and AEST/2020/029).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Dynamics of HDL-Cholesterol Following a Post-Myocardial Infarction Cardiac Rehabilitation Program

  • Bertolin-Boronat, C
  • Merenciano-Gonzalez H
  • Marcos-Garcés, Víctor
  • Martínez-Mas, Maria Luz
  • Climent Alberola, Josefa Ines
  • Pérez, Nerea
  • López-Bueno, Laura
  • Esteban-Argente, Maria Concepcion
  • Reig, Maria
  • Arizon Benito, Ana
  • Paya Rubio, Alfonso
  • Rios-Navarro, César
  • De Dios, Elena
  • Gavara-Doñate, Josep|||0000-0002-3483-7066
[EN] Background: Exercise-based cardiac rehabilitation programs (CRP) are recommended for patients following acute coronary syndrome to potentially improve high-density lipoprotein cholesterol (HDL-C) levels and prognosis. However, not all patients reach target HDL-C levels. Here we analyze the dynamics and predictors of HDL-C increase during CRP in patients following ST-segment elevation myocardial infarction or occlusion myocardial infarction. Methods: We conducted a prospective study of myocardial infarction patients who completed exercise-based Phase 2 CRP. Data was collected on clinical variables, cardiovascular risk factors, treatment goals, pharmacological therapy, and health outcomes through questionnaires at the beginning and at the end of Phase 2 CRP. Lipid profile analysis was performed before discharge, 4 to 6 weeks after discharge, and at the end of Phase 2 CRP. Changes in lipid profiles were evaluated, and predictors of failure to increase HDL-C levels were identified by binary logistic regression analysis. Results: Our cohort comprised 121 patients (mean age 61.67 +/- 10.97 years, 86.8% male, and 47.9% smokers before admission). A significant decrease in total cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) were noted, along with an increase in HDL-C (43.87 +/- 9.18 vs. 39.8 +/- 10.03 mg/dL, p < 0.001). Patients achieving normal HDL-C levels (>40 mg/dL in men and >50 mg/dL in women) significantly increased from 34.7% at admission to 52.9% the end of Phase 2. Multivariable analysis revealed smoking history (hazard ratio [HR] = 0.35, 95% confidence interval [CI], 0.11-0.96, p = 0.04), increased reduction in total cholesterol (HR = 0.94, 95% CI, 0.89-0.98, p = 0.004), and increased reduction in LDL-C (HR = 0.94, 95% CI, 0.89-0.99, p = 0.01) were inversely associated with failure to increase HDL-C levels. Conversely, higher HDL-C before CRP (HR = 1.15, 95% CI, 1.07-1.23, p < 0.001) and increased lipoprotein (a) (HR = 1.01, 95% CI, 1-1.02, p = 0.04) predicted failure to increase HDL-C levels. No significant correlations were found with Mediterranean diet adherence, weekly physical activity, training modalities, or physical fitness parameters. Conclusions: Participation in an exercise-based Phase 2 CRP led to mild but significant increases in HDL-C. Smoking history and patients experiencing substantial reductions in total cholesterol and LDL-C were more likely to experience HDL-C increases, unlike those with higher HDL-C and lipoprotein (a) levels before CRP., This research was funded by Instituto de Salud Carlos III, Fondos Europeos de Desarrollo Regional FEDER and Fondo Social Europeo Plus (FSE+) (grant numbers PI20/00637, PI23/01150, CIBERCV16/11/00486, CIBERCV16/11/00420, CIBERCV16/11/00479 and postgraduate contracts CM21/00175 and CM23/00246) and by Conselleria de Educación of the Generalitat Valenciana (PROMETEO/2021/008). Dr. Marcos-Garcés acknowledges funding from the Instituto de Salud Carlos III and co-funding from Fondo Social Europeo Plus (FSE+) (grant number JR23/00032), as well as a GE 2023 grant from the Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital of the Generalitat Valenciana (CIGE/2022/26). Drs. Ríos-Navarro and Gavara acknowledge funding from the Conselleria de Educación Generalitat Valenciana and co-funding from Fondo Social Europeo Plus (grant numbers CIAPOS/2023/247 and CIAPOS2023/248)
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Familial Hypercholesterolemia Screening in a Cardiac Rehabilitation Program After Myocardial Infarction

  • Bertolin-Boronat, Carlos
  • Marcos-Garcés, Víctor
  • Merenciano-Gonzalez, Héctor
  • Martínez Mas, Maria Luz
  • Climent Alberola, Josefa Inés
  • Pérez, Nerea
  • Lopez Bueno, Laura
  • Esteban Argente, Maria Concepcion
  • Valls Reig, Maria
  • Arizon Benito, Ana
  • Paya Rubio, Alfonso
  • Rios-Navarro, César
  • De Dios, Elena
  • Jiménez-Navarro, Manuel F.
  • Gavara-Doñate, Josep|||0000-0002-3483-7066
[EN] Familial hypercholesterolemia (FH) is relatively prevalent in myocardial infarction (MI) sufferers, and its diagnosis could improve preventive treatment in family members. We aim to analyze the diagnosis of FH and the rate of genetic testing in a prospective cohort of 245 patients submitted to our Cardiac Rehabilitation Program (CRP) after MI. Baseline characteristics were registered, and basal low-density lipoprotein cholesterol (LDL-C) was calculated after correction for lipid-lowering therapies (LLT) before or during admission. Simplified Dutch Lipid Clinic Network Scores (sDLCNS) were retrospectively calculated based on personal and familial history of premature cardiovascular disease and basal LDL-C levels. Mean age was 62.19 +/- 13.93 years, and most patients were male (81.6%). Mean LDL-C before admission and basal LDL-C corrected for LLT were 131.79 +/- 45.34 mg/dL and 162.87 +/- 44.17 mg/dL, respectively. Patients in the cohort were retrospectively categorized in the "unlikely" (<3 points; n = 162, 66.1%), "possible" (3-5 points; n = 72, 29.4%) and "probable" (6-8 points; n = 11, 4.5%) sDLCNS categories. Genetic testing for FH was requested in four (1.6%) patients, and no clinically significant genetic variants were detected. Patients who underwent genetic testing depicted significantly higher basal LDL-C (233 +/- 49.09 vs. 161.71 +/- 43.25 mg/dL, p = 0.001). However, the rate of individuals undergoing genetic testing was negligible even in the "possible" (n = 2, 2.8%) and "probable" (n = 1, 9.1%) sDLCNS categories. In conclusion, genetic testing for FH in our CRP after MI is largely underutilized, even in patients with a "possible" or "probable" diagnosis based on sDLCNS criteria, which represent about a third of the cohort. Strategies to improve screening for FH should be prospectively implemented., This work was supported by grants from "Instituto de Salud Carlos III", "Fondos Europeos de Desarrollo Regional FEDER" and "Fondo Social Europeo Plus (FSE+)" (grant numbers PI20/00637, PI23/01150, and CIBERCV16/11/00486, a postgraduate contract FI18/00320 to C.R.-N., CM23/00246 to H.M.-G., and CM21/00175 and JR23/00032 to V.M.-G.) and Conselleria de Educacion-Generalitat Valenciana (PROMETEO/2021/008). C.R.-N. and J.G. acknowledge funding from the Conselleria de Educacion-Generalitat Valenciana and co-funding from Fondo Social Europeo Plus (grant numbers CIAPOS/2023/247, and CIAPOS2023/248).
Repositori Institucional UIB
Publication Artículo científico (JournalArticle)

Contribution of cardio-vascular risk factors to depressive status in the PREDIMED-PLUS Trial. A cross-sectional and a 2-year longitudinal study

  • Martín-Peláez, Sandra
  • Serra-Majem, Lluis
  • Cano-Ibáñez, Naomi
  • Martínez-González, Miguel Ángel
  • Salas-Salvadó, Jordi
  • Corella, Dolores
  • Lassale, Camille
  • Martínez, Jose Alfredo
  • Alonso-Gómez, Ángel M.
  • Wärnberg, Julia
  • Vioque, Jesús
  • Romaguera, Dora
  • López-Miranda, José
  • Estruch, Ramón
  • Tinahones, Francisco J.
  • Lapetra, José
  • Fernández-Aranda, Fernando
  • Bueno-Cavanillas, Aurora
  • Tur, Josep A.
  • Martín, Vicente
  • Pintó, Xavier
  • Delgado-Rodríguez, Miguel
  • Matía, Pilar
  • Vidal, Josep
  • Vázquez, Clotilde
  • Daimiel, Lidia
  • Ros, Emili
  • Toledo, Estefanía
  • Nishi, Stephanie K.
  • Sorli, Jose V.
  • Malcampo, Mireia
  • Zulet, M. Ángeles
  • Moreno-Rodríguez, Anaí
  • Cueto-Galán, Raquel
  • Vivancos-Aparicio, Diego
  • Colom, Antoni
  • García-Ríos, Antonio
  • Casas, Rosa
  • Bernal-López, M. Rosa
  • Santos-Lozano, Jose Manuel
  • Vázquez, Zenaida
  • Gómez-Martínez, Carlos
  • Ortega-Azorín, Carolina
  • Del Val, Jose Luís
  • Abete, Itziar
  • Goikoetxea-Bahon, Amaia
  • Pascual, Elena
  • Becerra-Tomás, Nerea
  • Chillarón, Juan J.
  • Sánchez-Villegas, Almudena
[eng] Background: Cardio-vascular disease and depression are thought to be closely related, due to shared risk factors. The aim of the study was to determine the association between cardio-vascular risk (CVR) factors and depressive status in a population (55–75 years) with metabolic syndrome (MetS) from the PREDIMED-Plus trial. Methods and findings: Participants were classified into three groups of CVR according to the Framingham-based REGICOR function: (1) low (LR), (2) medium (MR) or (3) high/very high (HR). The Beck Depression Inventory-II (BDI-II) was used to assess depressive symptoms at baseline and after 2 years. The association between CVR and depressive status at baseline (n = 6545), and their changes after 2 years (n = 4566) were evaluated through multivariable regression models (logistic and linear models). HR women showed higher odds of depressive status than LR [OR (95% CI) = 1.78 (1.26, 2.50)]. MR and HR participants with total cholesterol <160 mg/mL showed higher odds of depression than LR [OR (95% CI) = 1.77 (1.13, 2.77) and 2.83 (1.25, 6.42) respectively)] but those with total cholesterol ≥280 mg/mL showed lower odds of depression than LR [OR (95% CI) = 0.26 (0.07, 0.98) and 0.23 (0.05, 0.95), respectively]. All participants decreased their BDI-II score after 2 years, being the decrease smaller in MR and HR diabetic compared to LR [adjusted mean±SE = -0.52±0.20, -0.41±0.27 and -1.25±0.31 respectively). MR and HR participants with total cholesterol between 240–279 mg/mL showed greater decreases in the BDI-II score compared to LR (adjusted mean±SE = -0.83±0.37, -0.77±0.64 and 0.97±0.52 respectively). Conclusions: Improving cardiovascular health could prevent the onset of depression in the elderly. Diabetes and total cholesterol in individuals at high CVR, may play a specific role in the precise response. International Standard Randomized Controlled Trial (ISRCTN89898870).
RUA. Repositorio Institucional de la Universidad de Alicante
Publication Otros (Other)

The pancreatic β-cell in ageing: Implications in age-related diabetes

  • Tudurí, Eva
  • Soriano, Sergi
  • Almagro, Lucía
  • Montanya, Eduard
  • Alonso Magdalena, Paloma
  • Nadal, Ángel
  • Quesada, Iván
  • Soriano, Sergi|||/items/8e3d590c-5b30-415a-93aa-bf5d4506efe4
  • Tudurí, Eva|||/items/ed03c763-6d0f-4b5a-a720-80238ac8cc4e
The prevalence of type 2 diabetes (T2D) and impaired glucose tolerance (IGT) increases with ageing. T2D generally results from progressive impairment of the pancreatic islets to adapt β-cell mass and function in the setting of insulin resistance and increased insulin demand. Several studies have shown an age-related decline in peripheral insulin sensitivity. However, a precise understanding of the pancreatic β-cell response in ageing is still lacking. In this review, we summarize the age-related alterations, adaptations and/or failures of β-cells at the molecular, morphological and functional levels in mouse and human. Age-associated alterations include processes such as β-cell proliferation, apoptosis and cell identity that can influence β-cell mass. Age-related changes also affect β-cell function at distinct steps including electrical activity, Ca2+ signaling and insulin secretion, among others. We will consider the potential impact of these alterations and those mediated by senescence pathways on β-cells and their implications in age-related T2D. Finally, given the great diversity of results in the field of β-cell ageing, we will discuss the sources of this heterogeneity. A better understanding of β-cell biology during ageing, particularly at older ages, will improve our insight into the contribution of β-cells to age-associated T2D and may boost new therapeutic strategies.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Similarity network fusion to identify phenotypes of small-for-gestational-age fetuses

  • Miranda, Jezid
  • Paules, Cristina
  • Noell, Guillaume
  • Youssef, Lina
  • Paternina-Caicedo, Angel
  • Crovetto, Francesca
  • Cañellas, Nicolau
  • Garcia-Martín, María L.
  • Amigó, Nuria
  • Eixarch, Elisenda
  • Faner, Rosa
  • Figueras, Francesc
  • Simões, Rui V.
  • Crispi, Fàtima
  • Gratacós, Eduard
Fetal growth restriction (FGR) affects 5–10% of pregnancies, is the largest contributor to fetal death, and can have long-term consequences for the child. Implementation of a standard clinical classification system is hampered by the multiphenotypic spectrum of small fetuses with substantial differences in perinatal risks. Machine learning and multiomics data can potentially revolutionize clinical decision-making in FGR by identifying new phenotypes. Herein, we describe a cluster analysis of FGR based on an unbiased machine-learning method. Our results confirm the existence of two subtypes of human FGR with distinct molecular and clinical features based on multiomic analysis. In addition, we demonstrated that clusters generated by machine learning significantly outperform single data subtype analysis and biologically support the current clinical classification in predicting adverse maternal and neonatal outcomes. Our approach can aid in the refinement of clinical classification systems for FGR supported by molecular and clinical signatures.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia

  • Vega-Garcia, Nerea
  • Benito, Rocío
  • Esperanza-Cebollada, Elena
  • Llop, Marta
  • Robledo, Cristina
  • Vicente-Garcés, Clara
  • Ortega Blanco, Margarita
Leucèmia limfoblàstica aguda infantil; Seqüenciació de nova generació, Leucemia linfoblástica aguda infantil; Secuenciación de nueva generación, Childhood acute lymphoblastic leukemia; Next-generation sequencing, The development of Next-Generation Sequencing (NGS) has provided useful diagnostic, prognostic, and therapeutic strategies for individualized management of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients. Consequently, NGS is rapidly being established in clinical practice. However, the technology’s complexity, bioinformatics analysis, and the different available options difficult a broad consensus between different laboratories in its daily routine introduction. This collaborative study among Spanish centers was aimed to assess the feasibility, pros, and cons of our customized panel and other commercial alternatives of NGS-targeted approaches. The custom panel was tested in three different sequencing centers. We used the same samples to assess other commercial panels (OncomineTM Childhood Cancer Research Assay; Archer®FusionPlex® ALL, and Human Comprehensive Cancer Panel GeneRead Panel v2®). Overall, the panels showed a good performance in different centers and platforms, but each NGS approach presented some issues, as well as pros and cons. Moreover, a previous consensus on the analysis and reporting following international guidelines would be preferable to improve the concordance in results among centers. Our study shows the challenges posed by NGS methodology and the need to consider several aspects of the chosen NGS-targeted approach and reach a consensus before implementing it in daily practice., This study has been supported by a grant from “Fundación Unoentrecienmil”; grants from Instituto de Salud Carlos III (PI12/02417; PI16/00246; PI12/00816; PI16CIII/00026; PI16/0665); Asociación Pablo Ugarte (TPY-M 1149/13; TRPV 205/18), ASION (TVP 141/17); Fundación Sonrisa de Alex & Todos somos Iván (TVP 1324/15); Consejería de Educación, Junta de Castilla y León (SA271P18); Fondos FEDER (CIBERONC [CB16/12/00284]), Proyectos de Investigación del SACYL, GRS 1847/A/18, Generalitat Valenciana GV2019/077 and Fundación AMPILE. J.M.H.S. is supported with a research grant by FEHH (“Fundación Española de Hematología y Hemoterapia”), A.M. a grant from Junta provincial de Salamanca de la Asociación Española Contra el Cáncer (AECC), and M.M. holds the grant “Ayuda predoctoral de la Junta de Castilla y León” by the Fondo Social Europeo (JCYL-EDU/556/2019 Ph.D. scholarship).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Efficacy of tocilizumab for hospitalized patients with COVID-19 pneumonia and high IL-6 levels: A randomized controlled trial

  • Augustin Recio, Salvador
  • Prió, Alba
  • Sellarès-Nadal, Júlia
  • Espinosa-Pereiro, Juan
  • Burgos, Joaquin
  • Falcó, Vicenç
  • Guillen-Del-Castillo, Alfredo
  • Bañares, Juan
  • Martínez-Valle, Fernando
  • Kirkegaard, Cristina
  • SÁNCHEZ-MONTALVÁ, ADRIÁN
Acute respiratory distress syndrome; COVID-19; Interleukin-6, Síndrome de dificultat respiratòria aguda; COVID-19; Interleucina-6, Síndrome de dificultad respiratoria aguda; COVID-19; Interleucina-6, Background The objective of this clinical trial is to evaluate the efficacy and safety of IL-6 driven personalized treatment strategy with tocilizumab in patients with severe COVID-19 pneumonia. Trial design Randomized, controlled, open-label, single-center trial of a tocilizumab treatment strategy in adult patients hospitalized with severe COVID-19 pneumonia and IL-6 serum levels > 40 pg/mL. Methods Patients were randomized 1:1 to receive standard of care (SOC) or SOC plus one dose of tocilizumab. The primary outcome was death or need for invasive mechanical ventilation (IMV) within 28 days after randomization. Secondary outcomes included ICU admission, days on IMV and hospital stay. A meta-analysis of clinical trials to evaluate the effect of tocilizumab on mortality and need of IMV in patients with COVID-19 pneumonia was performed. Results Sixty-two patients were included: 30 in the SOC arm and 32 in the standard-treatment plus tocilizumab arm. The primary outcome occurred in 12.9% in the tocilizumab arm and 32.3% in the SOC arm(p = 0.068). There was a trend towards fewer days on IMV (7.5 vs 19.5 days, p = 0.073) and a shorter hospital stay (4 vs 8 days, p = 0.134) in the tocilizumab group. No serious adverse events were reported. The meta-analysis revealed a RR for death or IMV of 0.83 (95% CI: 0.77–0.89) in patients receiving tocilizumab, compared to patients receiving SOC. Conclusion Tocilizumab could be effective to prevent death or IMV in patients with severe COVID-19 pneumonia and high IL-6 serum levels. Safety profile of tocilizumab does not arise major concern in patients with severe COVID19., Open Access Funding provided by Universitat Autonoma de Barcelona. This study received support of “Plataforma ISCIII de Soporte para la Investigación Clínica—SCReN (Spanish Clinical Research Network)” which is funded by ISCIII through the project sPT17/0017/0030 and PT20/00078, which are both integrated in the “Plan Estatal de I + D + I 2013–2016 y 2017–2020” and co-funded by the “ Fondo Europeo de Desarrollo Regional (FEDER) “Una manera de hacer Europa””. ASM was supported by the Instituto de Salud Carlos III (Juan Rodés postdoctoral fellowship grant number JR18/00022) during the study period. JSN and JEP are supported by the Instituto de Salud Carlos III (Rio Hortega predoctoral grant numbers CM22/00262 and CM22/00246).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Disrupted functional connectivity in adolescent obesity

  • Moreno-López, Laura
  • Contreras Rodríguez, Oren|||0000-0001-8922-8084
  • Soriano-Mas, Carles|||0000-0003-4574-6597
  • Stamatakis, Emmanuel A.
  • Verdejo-García, Antonio
Obesity has been associated with brain alterations characterised by poorer interaction between a hypersensitive reward system and a comparatively weaker prefrontal-cognitive control system. These alterations may occur as early as in adolescence, but this notion remains unclear, as no studies so far have examined global functional connectivity in adolescents with excess weight. We investigated functional connectivity in a sample of 60 adolescents with excess weight and 55 normal weight controls. We first identified parts of the brain displaying between-group global connectivity differences and then characterised the extent of the differences in functional network integrity and their association with reward sensitivity. Adolescent obesity was linked to neuroadaptations in functional connectivity within brain hubs linked to interoception (insula), emotional memory (middle temporal gyrus) and cognitive control (dorsolateral prefrontal cortex) (pFWE < 0.05). The connectivity between the insula and the anterior cingulate cortex was reduced in comparison to controls, as was the connectivity between the middle temporal gyrus and the posterior cingulate cortex and cuneus/precuneus (pFWE < 0.05). Conversely, the middle temporal gyrus displayed increased connectivity with the orbitofrontal cortex (pFWE < 0.05). Critically, these networks were correlated with sensitivity to reward (p < 0.05). These findings suggest that adolescent obesity is linked to disrupted functional connectivity in brain networks relevant to maintaining balance between reward, emotional memories and cognitive control. Our findings may contribute to reconceptualization of obesity as a multi-layered brain disorder leading to compromised motivation and control, and provide a biological account to target prevention strategies for adolescent obesity
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia

  • Vega-Garcia, Nerea
  • Benito, Rocío|||0000-0001-9781-4198
  • Esperanza-Cebollada, Elena|||0000-0001-5451-0370
  • Llop, Marta
  • Robledo, Cristina|||0000-0003-0445-3210
  • Vicente-Garcés, Clara|||0000-0002-2556-043X
  • Alonso, Javier|||0000-0002-6287-8391
  • Barragán, Eva
  • Fernández, Guerau
  • Hernández-Sánchez, Jesús M.
  • Martín-Izquierdo, Marta
  • Maynou, Joan
  • Minguela, Alfredo|||0000-0003-2472-5893
  • Montaño, Adrián|||0000-0002-3178-6726
  • Ortega, Margarita
  • Torrebadell, Montserrat
  • Cervera, José|||0000-0001-8252-1106
  • Sánchez, Joaquín
  • Jiménez-Velasco, Antonio|||0000-0001-6421-7872
  • Riesco, Susana
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
  • Lassaletta, Álvaro|||0000-0003-2881-1473
  • Fernández, José María
  • Rives, Susana|||0000-0002-5658-1831
  • Dapena, José Luis|||0000-0002-6711-7479
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Camós, Mireia|||0000-0003-3658-7942
The development of Next-Generation Sequencing (NGS) has provided useful diagnostic, prognostic, and therapeutic strategies for individualized management of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients. Consequently, NGS is rapidly being established in clinical practice. However, the technology's complexity, bioinformatics analysis, and the different available options difficult a broad consensus between different laboratories in its daily routine introduction. This collaborative study among Spanish centers was aimed to assess the feasibility, pros, and cons of our customized panel and other commercial alternatives of NGS-targeted approaches. The custom panel was tested in three different sequencing centers. We used the same samples to assess other commercial panels (Oncomine TM Childhood Cancer Research Assay; Archer ® FusionPlex ® ALL, and Human Comprehensive Cancer Panel GeneRead Panel v2 ®). Overall, the panels showed a good performance in different centers and platforms, but each NGS approach presented some issues, as well as pros and cons. Moreover, a previous consensus on the analysis and reporting following international guidelines would be preferable to improve the concordance in results among centers. Our study shows the challenges posed by NGS methodology and the need to consider several aspects of the chosen NGS-targeted approach and reach a consensus before implementing it in daily practice.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Emotion Regulation and Excess Weight, Impaired Affective Processing Characterized by Dysfunctional Insula Activation and Connectivity

  • Steward, Trevor|||0000-0003-3116-8175
  • Picó-Pérez, Maria|||0000-0002-1573-2445
  • Mata, Fernanda
  • Martínez-Zalacaín, Ignacio|||0000-0002-4036-0284
  • Cano, Marta|||0000-0003-0675-9483
  • Contreras Rodríguez, Oren|||0000-0001-8922-8084
  • Fernández Aranda, Fernando|||0000-0002-2968-9898
  • Yücel, Murat|||0000-0002-4705-452X
  • Soriano-Mas, Carles|||0000-0003-4574-6597
  • Verdejo-García, Antonio
Emotion-regulation strategies are understood to influence food intake. This study examined the neurophysiological underpinnings of negative emotion processing and emotion regulation in individuals with excess weight compared to normal-weight controls. Fifteen participants with excess-weight (body mass index.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Effects of a psychosocial intervention at one-year follow-up in a PREDIMED-plus sample with obesity and metabolic syndrome

  • Mallorquí-Bagué, Núria|||0000-0003-1434-3162
  • Lozano Madrid, María|||0000-0003-3833-317X
  • Vintró Alcaraz, Cristina|||0000-0001-9453-8810
  • Forcano, Laura|||0000-0002-8478-1451
  • Díaz-López, Andrés|||0000-0002-7500-5629
  • Galera, Ana
  • Fernández-Carrión, Rebeca
  • Granero, Roser|||0000-0001-6308-3198
  • Jiménez Murcia, Susana|||0000-0002-3596-8033
  • Corella, Dolores|||0000-0002-2366-4104
  • Pintó, Xavier|||0000-0002-2216-2444
  • Cuenca-Royo, Aida|||0000-0001-8551-5457
  • Bulló, Mònica|||0000-0002-0218-7046
  • Salas-Salvadó, Jordi|||0000-0003-2700-7459
  • Torre, Rafael de la|||0000-0002-6765-1866
  • Fernández Aranda, Fernando|||0000-0002-2968-9898
This study examines if overweight/obesity are related to higher impulsivity, food addiction and depressive symptoms, and if these variables could be modified after 1 year of a multimodal intervention (diet, physical activity, psychosocial support). 342 adults (55-75 years) with overweight/obesity and metabolic syndrome (MetS) from the PREDIMED-Plus Cognition study were randomized to the intervention or to the control group (lifestyle recommendations). Cognitive and psychopathological assessments were performed at baseline and after 1-year follow-up. At baseline, higher impulsivity was linked to higher food addiction and depressive symptoms, but not to body mass index (BMI). Food addiction not only predicted higher BMI and depressive symptoms, but also achieved a mediational role between impulsivity and BMI/depressive symptoms. After 1 year, patients in both groups reported significant decreases in BMI, food addiction and impulsivity. BMI reduction and impulsivity improvements were higher in the intervention group. Higher BMI decrease was achieved in individuals with lower impulsivity. Higher scores in food addiction were also related to greater post-treatment impulsivity. To conclude, overweight/obesity are related to higher impulsivity, food addiction and depressive symptoms in mid/old age individuals with MetS. Our results also highlight the modifiable nature of the studied variables and the interest of promoting multimodal interventions within this population.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Lifetime Weight Course as a Phenotypic Marker of Severity and Therapeutic Response in Patients with Eating Disorders

  • Agüera, Zaida|||0000-0003-4453-4939
  • Vintró Alcaraz, Cristina|||0000-0001-9453-8810
  • Baenas Soto, Isabel Maria|||0000-0001-7415-0616
  • Granero, Roser|||0000-0001-6308-3198
  • Sánchez Díaz, Isabel María|||0000-0001-5874-8204
  • Sánchez González, Jéssica|||0000-0002-9327-0100
  • Menchón Magriñá, José Manuel|||0000-0002-6231-6524
  • Jiménez Murcia, Susana|||0000-0002-3596-8033
  • Treasure, Janet|||0000-0003-0871-4596
  • Fernández Aranda, Fernando|||0000-0002-2968-9898
The association between lifetime weight fluctuations and clinical characteristics has been widely studied in populations with eating disorders (ED). However, there is a lack of literature examining the potential role of weight course as a transdiagnostic factor in ED so far. Therefore, the aim of this study is to compare ED severity and treatment outcomes among four specific BMI profiles based on BMI-trajectories across the lifespan: (a) persistent obesity (OB-OB; (n = 74)), (b) obesity in the past but currently in a normal weight range (OB-NW; n = 156), (c) normal weight throughout the lifespan (NW-NW; n = 756), and (d) current obesity but previously at normal weight (NW-OB; n = 314). Lifetime obesity is associated with greater general psychopathology and personality traits such as low persistence and self-directedness, and high reward dependence. Additionally, greater extreme weight changes (NW-OB and OB-NW) were associated with higher psychopathology but not with greater ED severity. Higher dropout rates were found in the OB-OB group. These results shed new light on the BMI trajectory as a transdiagnostic feature playing a pivotal role in the severity and treatment outcome in patients with ED.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Neuropsychological Learning Deficits as Predictors of Treatment Outcome in Patients with Eating Disorders

  • Lucas Adell, Ignacio|||0000-0001-9426-5082
  • Miranda-Olivos, Romina|||0000-0003-2360-5830
  • Testa, Giulia|||0000-0003-4200-8062
  • Granero, Roser|||0000-0001-6308-3198
  • Sánchez Díaz, Isabel María|||0000-0001-5874-8204
  • Sánchez González, Jéssica|||0000-0002-9327-0100
  • Jiménez Murcia, Susana|||0000-0002-3596-8033
  • Fernández Aranda, Fernando|||0000-0002-2968-9898
Eating disorders (EDs) are severe psychiatric illnesses that require individualized treatments. Decision-making deficits have been associated with EDs. Decision-making learning deficits denote a lack of strategies to elaborate better decisions that can have an impact on recovery and response to treatment. This study used the Iowa Gambling Task (IGT) to investigate learning differences related to treatment outcome in EDs, comparing between patients with a good and bad treatment outcome and healthy controls. Likewise, the predictive role of impaired learning performance on therapy outcome was explored. Four hundred twenty-four participants (233 ED patients and 191 healthy controls) participated in this study. Decision making was assessed using the Iowa Gambling Task before any psychological treatment. All patients received psychological therapy, and treatment outcome was evaluated at discharge. Patients with bad outcome did not show progression in the decision-making task as opposed to those with good outcome and the healthy control sample. Additionally, learning performance in the decision-making task was predictive of their future outcome. The severity of learning deficits in decision making may serve as a predictor of the treatment. These results may provide a starting point of how decision-making learning deficits are operating as dispositional and motivational factors on responsiveness to treatment in EDs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Food addiction and lifetime alcohol and illicit drugs use in specific eating disorders

  • Miranda-Olivos, Romina|||0000-0003-2360-5830
  • Agüera, Zaida|||0000-0003-4453-4939
  • Granero, Roser|||0000-0001-6308-3198
  • Vergeer, Rhianna R.
  • Dieguez, Carlos|||0000-0002-0919-4337
  • Jiménez Murcia, Susana|||0000-0002-3596-8033
  • Gearhardt, Ashley N.|||0000-0003-3843-5731
  • Fernández Aranda, Fernando|||0000-0002-2968-9898
Food addiction (FA) and substance use (SU) have frequently been reported in patients with eating disorders (EDs). Our study aimed to assess the prevalence rates of FA and/or lifetime problematic alcohol and illicit drug use among patients with specific ED, such as: bulimia nervosa (BN), binge eating disorder (BED), and other specified feeding and eating disorder (OSFED). We sought to identify clinical, psychopathological, and personality profiles involved in these addictive behavior-based phenotypes. The total sample was 527 patients (176 BN, 115 BED, and 236 OSFED). FA was assessed through the Yale Food Addiction Scale 2.0. To determine lifetime SU, a semi-structured clinical interview was carried out. Patients with BN had the highest rates of FA both with and without SU. No gender differences were obtained for the prevalence of current FA and/or lifetime SU. Patients reporting at least one addictive-related behavior exhibited increased clinical severity compared to those who reported none. Increased impulsivity (such as high lack of premeditation, sensation seeking, and positive urgency) and low self-directedness were differentiating factors for presenting one or two addictive behaviors. Overall, patients presenting with at least one addictive-like behavior reported a poorer clinical status than those without. Also, patients with FA and SU exhibited a more dysfunctional profile characterized by high impulsivity and low self-directedness. These findings would support the need for targeted treatments to reduce impulsivity and increase self-directedness, especially in patients with any addictive-related behavior, as a step towards improving their treatment outcome.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Emotional regulation in eating disorders and gambling disorder, A transdiagnostic approach

  • Munguía Godínez, Jazmín Lucero|||0000-0002-9751-810X
  • Jiménez Murcia, Susana|||0000-0002-3596-8033
  • Granero, Roser|||0000-0001-6308-3198
  • Baenas Soto, Isabel Maria|||0000-0001-7415-0616
  • Agüera, Zaida|||0000-0003-4453-4939
  • Sánchez Díaz, Isabel María|||0000-0001-5874-8204
  • Codina, Ester|||0000-0002-0848-0614
  • Pino Gutiérrez, Amparo del|||0000-0002-2854-9850
  • Testa, Giulia|||0000-0003-4200-8062
  • Treasure, Janet|||0000-0003-0871-4596
  • Fernández Aranda, Fernando|||0000-0002-2968-9898
Difficulties in Emotion Regulation (ER) are related to the etiology and maintenance of several psychological disorders, including Eating Disorders (ED) and Gambling Disorder (GD). This study explored the existence of latent empirical groups between both disorders, based on ER difficulties and considering a set of indicators of personality traits, the severity of the disorder, and psychopathological distress. The sample included 1,288 female and male participants, diagnosed with ED (n = 906) and GD (n = 382). Two-step clustering was used for the empirical classification, while analysis of variance and chi-square tests were used for the comparison between the latent groups. Three empirical groups were identified, from the most disturbed ER profile (Subgroup 1) to the most functional (Subgroup 3). The ER state showed a linear relationship with the severity of each disorder and the psychopathological state. Different personality traits were found to be related to the level of emotion dysregulation. In this study, three distinct empirical groups based on ER were identified across ED and GD, suggesting that ER is a transdiagnostic construct. These findings may lead to the development of common treatment strategies and more tailored approaches.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment

  • Vega-García, Nerea
  • Perez-Jaume, Sara
  • Esperanza-Cebollada, Elena|||0000-0001-5451-0370
  • Vicente-Garcés, Clara|||0000-0002-2556-043X
  • Torrebadell, Montserrat
  • Jiménez-Velasco, Antonio|||0000-0001-6421-7872
  • Ortega-Blanco, Margarita
  • Llop, Marta
  • Abad, Lorea
  • Vagace Valero, José Manuel|||0000-0001-8751-4319
  • Minguela, Alfredo|||0000-0003-2472-5893
  • Pratcorona, Marta|||0000-0001-6375-596X
  • Sánchez-Garcia, Joaquin
  • García-Calderón, Clara B.
  • Gómez-Casares, María Teresa
  • Martín-Clavero, Estela
  • Escudero, Adela
  • Riñón Martinez-Gallo, Marta
  • Muñoz, Luz
  • Velasco, María Rosario
  • García-Morin, Marina|||0000-0003-1405-2912
  • Català, Albert|||0000-0003-0133-1752
  • Pascual, Antonia
  • Velasco Puyo, Pablo|||0000-0001-7331-9483
  • Fernández, José María
  • Lassaletta, Álvaro|||0000-0003-2881-1473
  • Fuster, José Luis|||0000-0002-4881-9440
  • Badell Serra, Isabel|||0000-0001-6546-2175
  • Molinos-Quintana, Águeda
  • Molinés, Antonio
  • Guerra-García, Pilar
  • Pérez Martínez, Antonio|||0000-0002-6436-9195
  • García-Abós, Miriam
  • Robles Ortiz, Reyes
  • Pisa Gatell, Sandra
  • Adán, Rosa
  • Díaz de Heredia, Cristina|||0000-0001-8086-296X
  • Dapena, José Luis|||0000-0002-6711-7479
  • Rives, Susana|||0000-0002-5658-1831
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Camós, Mireia|||0000-0003-3658-7942
Robust and applicable risk-stratifying genetic factors at diagnosis in pediatric T-cell acute lymphoblastic leukemia (T-ALL) are still lacking, and most protocols rely on measurable residual disease (MRD) assessment. In our study, we aimed to analyze the impact of NOTCH1, FBXW7, PTEN, and RAS mutations, the measurable residual disease (MRD) levels assessed by flow cytometry (FCM-MRD) and other reported risk factors in a Spanish cohort of pediatric T-ALL patients. We included 199 patients treated with SEHOP and PETHEMA consecutive protocols from 1998 to 2019. We observed a better outcome of patients included in the newest SEHOP-PETHEMA-2013 protocol compared to the previous SHOP-2005 cohort. FCM-MRD significantly predicted outcome in both protocols, but the impact at early and late time points differed between protocols. The impact of FCM-MRD at late time points was more evident in SEHOP-PETHEMA 2013, whereas in SHOP-2005 FCM-MRD was predictive of outcome at early time points. Genetics impact was different in SHOP-2005 and SEHOP-PETHEMA-2013 cohorts: NOTCH1 mutations impacted on overall survival only in the SEHOP-PETHEMA-2013 cohort, whereas homozygous deletions of CDKN2A/B had a significantly higher CIR in SHOP-2005 patients. We applied the clinical classification combining oncogenetics, WBC count and MRD levels at the end of induction as previously reported by the FRALLE group. Using this score, we identified different subgroups of patients with statistically different outcome in both Spanish cohorts. In SHOP-2005, the FRALLE classifier identified a subgroup of high-risk patients with poorer survival. In the newest protocol SEHOP-PETHEMA-2013, a very low-risk group of patients with excellent outcome and no relapses was detected, with borderline significance. Overall, FCM-MRD, WBC count and oncogenetics may refine the risk-stratification, helping to design tailored approaches for pediatric T-ALL patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cord Blood Cardiovascular Biomarkers in Left-Sided Congenital Heart Disease

  • Soveral, Iris|||0000-0002-3571-1780
  • Guirado, Laura
  • Escobar-Diaz, Maria C.|||0000-0001-9875-3593
  • Alcaide, María José|||0000-0003-3472-8107
  • Martínez Crespo, Josep Maria
  • Rodríguez Sureda, Víctor|||0000-0003-4942-9249
  • Bijnens, Bart
  • Antolin, Eugenia
  • Llurba, Elisa|||0000-0003-4048-6407
  • Bartha, José Luis
  • Gómez, Olga|||0000-0003-4183-9876
  • Crispi, Fatima|||0000-0002-7422-5240
Fetal echocardiography has limited prognostic ability in the evaluation of left-sided congenital heart defects (left heart defects). Cord blood cardiovascular biomarkers could improve the prognostic evaluation of left heart defects. A multicenter prospective cohort (2013-2019) including fetuses with left heart defects (aortic coarctation, aortic stenosis, hypoplastic left heart, and multilevel obstruction (complex left heart defects) subdivided according to their outcome (favorable vs. poor), and control fetuses were evaluated in the third trimester of pregnancy at three referral centers in Spain. Poor outcome was defined as univentricular palliation, heart transplant, or death. Cord blood concentrations of N-terminal precursor of B-type natriuretic peptide, Troponin I, transforming growth factor β, placental growth factor, and soluble fms-like tyrosine kinase-1 were determined. A total of 45 fetuses with left heart defects (29 favorable and 16 poor outcomes) and 35 normal fetuses were included, with a median follow-up of 3.1 years (interquartile range 1.4-3.9). Left heart defects with favorable outcome showed markedly increased cord blood transforming growth factor β (normal heart median 15.5 ng/mL (6.8-21.4) vs. favorable outcome 51.7 ng/mL (13.8-73.9) vs. poor outcome 25.1 ng/mL (6.9-39.0), p = 0.001) and decreased placental growth factor concentrations (normal heart 17.9 pg/mL (13.8-23.9) vs. favorable outcome 12.8 pg/mL (11.7-13.6) vs. poor outcome 11.0 pg/mL (8.8-15.4), p < 0.001). Poor outcome left heart defects had higher N-terminal precursor of B-type natriuretic peptide (normal heart 508.0 pg/mL (287.5-776.3) vs. favorable outcome 617.0 pg/mL (389.8-1087.8) vs. poor outcome 1450.0 pg/mL (919.0-1645.0), p = 0.001) and drastically reduced soluble fms-like tyrosine kinase-1 concentrations (normal heart 1929.7 pg/mL (1364.3-2715.8) vs. favorable outcome (1848.3 pg/mL (646.9-2313.6) vs. poor outcome 259.0 pg/mL (182.0-606.0), p < 0.001). Results showed that fetuses with left heart defects present a distinct cord blood biomarker profile according to their outcome.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Association of circulating microRNAs with coronary artery disease and usefulness for reclassification of healthy individuals, The REGICOR study

  • Degano, Irene R.|||0000-0003-1914-6934
  • Camps-Vilaró, Anna|||0000-0001-9644-8421
  • Subirana, Isaac|||0000-0003-1676-0197
  • García-Mateo, Nadia
  • Cidad, Pilar
  • Muñoz Aguayo, Daniel|||0000-0001-8173-0168
  • Puigdecanet, Eulàlia|||0000-0001-6067-9332
  • Nonell, Lara|||0000-0002-8538-8213
  • Vila-Domènech, Joan Salvador|||0000-0002-0413-9291
  • Crepaldi, Felipe Mingorance|||0000-0002-8500-1162
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Pérez-García, María Teresa|||0000-0001-8540-8117
  • Elosua, Roberto|||0000-0001-8235-0095
  • Fitó, Montserrat|||0000-0002-1817-483X
  • Marrugat, Jaume|||0000-0003-3320-554X
Risk prediction tools cannot identify most individuals at high coronary artery disease (CAD) risk. Oxidized low-density lipoproteins (oxLDLs) and microRNAs are actively involved in atherosclerosis. Our aim was to examine the association of CAD and oxLDLs-induced microRNAs, and to assess the microRNAs predictive capacity of future CAD events. Human endothelial and vascular smooth muscle cells were treated with oxidized/native low-density lipoproteins, and microRNA expression was analyzed. Differentially expressed and CAD-related miRNAs were examined in serum samples from (1) a case-control study with 476 myocardial infarction (MI) patients and 487 controls, and (2) a case-cohort study with 105 incident CAD cases and 455 randomly-selected cohort participants. MicroRNA expression was analyzed with custom OpenArray plates, log rank tests and Cox regression models. Twenty-one microRNAs, two previously undescribed (hsa-miR-193b-5p and hsa-miR-1229-5p), were up- or down-regulated upon cell treatment with oxLDLs. One of the 21, hsa-miR-122-5p, was also upregulated in MI cases (fold change = 4.85). Of the 28 CAD-related microRNAs tested, 11 were upregulated in MI cases -1 previously undescribed (hsa-miR-16-5p)-, and 1/11 was also associated with CAD incidence (adjusted hazard ratio = 0.55 (0.35-0.88)) and improved CAD risk reclassification, hsa-miR-143-3p. We identified 2 novel microRNAs modulated by oxLDLs in endothelial cells, 1 novel microRNA upregulated in AMI cases compared to controls, and one circulating microRNA that improved CAD risk classification.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Endothelial activation and damage as a common pathological substrate in different pathologies and cell therapy complications

  • Palomo, Marta|||0000-0002-3261-6577
  • Moreno-Castaño, Ana Belén|||0000-0003-0338-7514
  • Salas, María Queralt|||0000-0003-4567-3682
  • Escribano Serrat, Silvia|||0000-0001-9499-8999
  • Rovira Argelagués, Montserrat|||0000-0001-7786-9079
  • Guillén-Olmos, Elena
  • Fernandez, Sara
  • Ventosa-Capell, Helena
  • Youssef, Lina|||0000-0002-0554-5507
  • Crispi, Fatima|||0000-0002-7422-5240
  • Nomdedeu, Meritxell
  • Martínez Sánchez, Julia
  • De Moner, Blanca
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
The endothelium is a biologically active interface with multiple functions, some of them common throughout the vascular tree, and others that depend on its anatomical location. Endothelial cells are continually exposed to cellular and humoral factors, and to all those elements (biological, chemical, or hemodynamic) that circulate in blood at a certain time. It can adapt to different stimuli but this capability may be lost if the stimuli are strong enough and/or persistent in time. If the endothelium loses its adaptability it may become dysfunctional, becoming a potential real danger to the host. Endothelial dysfunction is present in multiple clinical conditions, such as chronic kidney disease, obesity, major depression, pregnancy-related complications, septic syndromes, COVID-19, and thrombotic microangiopathies, among other pathologies, but also in association with cell therapies, such as hematopoietic stem cell transplantation and treatment with chimeric antigen receptor T cells. In these diverse conditions, evidence suggests that the presence and severity of endothelial dysfunction correlate with the severity of the associated disease. More importantly, endothelial dysfunction has a strong diagnostic and prognostic value for the development of critical complications that, although may differ according to the underlying disease, have a vascular background in common. Our multidisciplinary team of women has devoted many years to exploring the role of the endothelium in association with the mentioned diseases and conditions. Our research group has characterized some of the mechanisms and also proposed biomarkers of endothelial damage. A better knowledge would provide therapeutic strategies either to prevent or to treat endothelial dysfunction.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Implications of noncoding regulatory functions in the development of insulinomas

  • Ramos-Rodríguez, Mireia
  • Subirana Granés, Marc
  • Norris, Richard|||0000-0001-8446-5507
  • Sordi, Valeria
  • Fernández, Esteve|||0000-0003-4239-723X
  • Fuentes-Páez, Georgina
  • Pérez-González, Beatriz|||0000-0001-9849-5176
  • Berenguer Balaguer, Clara
  • Raurell-Vila, Helena
  • Chowdhury, Murad
  • Corripio, Raquel|||0000-0003-3344-8269
  • Partelli, Stefano
  • López-Bigas, Núria
  • Pellegrini, Silvia
  • Montanya, Eduard|||0000-0003-2518-9076
  • Nacher Garcia, Montserrat|||0000-0002-8458-9275
  • Falconi, Massimo
  • Layer, R.
  • Rovira, Meritxell|||0000-0002-0538-4846
  • González-Pérez, A.
  • Piemonti, Lorenzo|||0000-0002-2172-2198
  • Pasquali, Lorenzo|||0000-0003-2423-1826
Insulinomas are rare neuroendocrine tumors arising from pancreatic β cells, characterized by aberrant proliferation and altered insulin secretion, leading to glucose homeostasis failure. With the aim of uncovering the role of noncoding regulatory regions and their aberrations in the development of these tumors, we coupled epigenetic and transcriptome profiling with whole-genome sequencing. As a result, we unraveled somatic mutations associated with changes in regulatory functions. Critically, these regions impact insulin secretion, tumor development, and epigenetic modifying genes, including polycomb complex components. Chromatin remodeling is apparent in insulinoma-selective domains shared across patients, containing a specific set of regulatory sequences dominated by the SOX17 binding motif. Moreover, many of these regions are H3K27me3 repressed in β cells, suggesting that tumoral transition involves derepression of polycomb-targeted domains. Our work provides a compendium of aberrant cis-regulatory elements affecting the function and fate of β cells in their progression to insulinomas and a framework to identify coding and noncoding driver mutations.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Null hypothesis significance tests, a misleading approach to scientific knowledge, some implications for eating disorders research

  • Granero, Roser|||0000-0001-6308-3198
  • Treasure, Janet|||0000-0003-0871-4596
  • Claes, Laurence|||0000-0002-2287-3158
  • Favaro, Andrea
  • Jiménez Murcia, Susana|||0000-0002-3596-8033
  • Karwautz, Andreas|||0000-0001-9053-998X
  • Le Grange, Daniel|||0000-0001-7293-9496
  • Tchanturia, Kate|||0000-0001-8988-3265
  • Fernández Aranda, Fernando|||0000-0002-2968-9898
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cognitive and clinical gender-related differences among binge-spectrum eating disorders, analysis of therapy response predictors

  • Mallorquí-Bagué, Núria|||0000-0003-1434-3162
  • Lozano Madrid, María|||0000-0003-3833-317X
  • Granero, Roser|||0000-0001-6308-3198
  • Mestre-Bach, Gemma|||0000-0001-5345-0484
  • Vintró Alcaraz, Cristina|||0000-0001-9453-8810
  • Sánchez Díaz, Isabel María|||0000-0001-5874-8204
  • Jiménez Murcia, Susana|||0000-0002-3596-8033
  • Fernández Aranda, Fernando|||0000-0002-2968-9898
Objective: This study assessed gender-related differences in executive functions (decision-making, inhibitory control and cognitive flexibility), personality traits and psychopathological symptoms in binge-spectrum eating disorders (EDs). Secondly, we aimed to separately explore the predictive value of gender and executive functions in treatment outcome. Method: A battery of self-reported and neurocognitive measures were answered by a sample of 85 patients (64 females) diagnosed with a binge-spectrum ED (41 BN; 44 binge eating disorder). Results: Data showed gender-related differences in executive functioning, displaying women lower inhibitory control and lower cognitive flexibility than men. Regarding personality traits and psychopathology symptoms, women presented higher reward dependence and cooperativeness, as well as more drive for thinness, body dissatisfaction, bulimia, and somatisation symptoms than men. Finally, worse executive functioning, particularly having lower ability in concept formation seems to predict worse treatment outcomes and dropout in these patients. Conclusions: We described gender specific neuropsychological, personality and psychopathological impairments in patients with binge-spectrum EDs. Moreover, difficulties in executive functioning might have an impact on treatment response, since patients with a lower ability in concept formation are less likely to benefit from treatment. The present results can help improving current treatment approaches by tackling gender and individual differences.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Where does purging disorder lie on the symptomatologic and personality continuum when compared to other eating disorder subtypes?, implications for the DSM

  • Krug, Isabel|||0000-0002-5275-3595
  • Giles, Sarah
  • Granero, Roser|||0000-0001-6308-3198
  • Agüera, Zaida|||0000-0003-4453-4939
  • Sánchez Díaz, Isabel María|||0000-0001-5874-8204
  • Sánchez González, Jéssica|||0000-0002-9327-0100
  • Jiménez Murcia, Susana|||0000-0002-3596-8033
  • Fernández Aranda, Fernando|||0000-0002-2968-9898
OBJECTIVES: To assess the clinical significance and distinctiveness of purging disorder (PD) from other eating disorder (ED) diagnoses. METHOD: Participants included 3127 women consecutively admitted to an ED treatment centre (246 PD, 465 anorexia nervosa restrictive [AN-R], 327 AN-binge purging [AN-BP], 1436 bulimia nervosa [BN], 360 binge eating disorder [BED], 177 atypical AN and 116 unspecified feeding or eating disorder [UFED]) who were diagnosed according to DSM-5 criteria. Additionally, 822 control participants were recruited from the community. All participants completed measures assessing ED symptoms (EDI-2), general psychopathology (SCL-90-R) and personality (TCI-R). RESULTS: Patients with PD, when compared to controls, scored significantly higher on the EDI-2 and SCL-90-R, and most TCI-R dimensions. Most of the significant differences between PD and the other ED diagnoses emerged between PD and AN-R, followed by Atypical-AN, UFED, AN-BP and BED, with patients with PD typically reporting higher scores on the EDI-2 and SCL-90-R subscales. Significant differences between PD and BN were also present, but to a lesser extent. The findings for personality varied amongst the different ED diagnoses. CONCLUSIONS: PD is a clinically significant disorder, which seems to be more similar to BN than it is to AN and the other ED subtypes.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia

  • Vega-Garcia, Nerea
  • Benito, Rocío
  • Esperanza-Cebollada, Elena
  • Llop, Marta
  • Robledo, Cristina
  • Vicente-Garcés, Clara
  • Ortega Blanco, Margarita
Leucèmia limfoblàstica aguda infantil; Seqüenciació de nova generació, Leucemia linfoblástica aguda infantil; Secuenciación de nueva generación, Childhood acute lymphoblastic leukemia; Next-generation sequencing, The development of Next-Generation Sequencing (NGS) has provided useful diagnostic, prognostic, and therapeutic strategies for individualized management of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients. Consequently, NGS is rapidly being established in clinical practice. However, the technology’s complexity, bioinformatics analysis, and the different available options difficult a broad consensus between different laboratories in its daily routine introduction. This collaborative study among Spanish centers was aimed to assess the feasibility, pros, and cons of our customized panel and other commercial alternatives of NGS-targeted approaches. The custom panel was tested in three different sequencing centers. We used the same samples to assess other commercial panels (OncomineTM Childhood Cancer Research Assay; Archer®FusionPlex® ALL, and Human Comprehensive Cancer Panel GeneRead Panel v2®). Overall, the panels showed a good performance in different centers and platforms, but each NGS approach presented some issues, as well as pros and cons. Moreover, a previous consensus on the analysis and reporting following international guidelines would be preferable to improve the concordance in results among centers. Our study shows the challenges posed by NGS methodology and the need to consider several aspects of the chosen NGS-targeted approach and reach a consensus before implementing it in daily practice., This study has been supported by a grant from “Fundación Unoentrecienmil”; grants from Instituto de Salud Carlos III (PI12/02417; PI16/00246; PI12/00816; PI16CIII/00026; PI16/0665); Asociación Pablo Ugarte (TPY-M 1149/13; TRPV 205/18), ASION (TVP 141/17); Fundación Sonrisa de Alex & Todos somos Iván (TVP 1324/15); Consejería de Educación, Junta de Castilla y León (SA271P18); Fondos FEDER (CIBERONC [CB16/12/00284]), Proyectos de Investigación del SACYL, GRS 1847/A/18, Generalitat Valenciana GV2019/077 and Fundación AMPILE. J.M.H.S. is supported with a research grant by FEHH (“Fundación Española de Hematología y Hemoterapia”), A.M. a grant from Junta provincial de Salamanca de la Asociación Española Contra el Cáncer (AECC), and M.M. holds the grant “Ayuda predoctoral de la Junta de Castilla y León” by the Fondo Social Europeo (JCYL-EDU/556/2019 Ph.D. scholarship).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Efficacy of tocilizumab for hospitalized patients with COVID-19 pneumonia and high IL-6 levels: A randomized controlled trial

  • Augustin Recio, Salvador
  • Prió, Alba
  • Sellarès-Nadal, Júlia
  • Espinosa-Pereiro, Juan
  • Burgos, Joaquin
  • Falcó, Vicenç
  • Guillen-Del-Castillo, Alfredo
  • Bañares, Juan
  • Martínez-Valle, Fernando
  • Kirkegaard, Cristina
  • SÁNCHEZ-MONTALVÁ, ADRIÁN
Acute respiratory distress syndrome; COVID-19; Interleukin-6, Síndrome de dificultat respiratòria aguda; COVID-19; Interleucina-6, Síndrome de dificultad respiratoria aguda; COVID-19; Interleucina-6, Background The objective of this clinical trial is to evaluate the efficacy and safety of IL-6 driven personalized treatment strategy with tocilizumab in patients with severe COVID-19 pneumonia. Trial design Randomized, controlled, open-label, single-center trial of a tocilizumab treatment strategy in adult patients hospitalized with severe COVID-19 pneumonia and IL-6 serum levels > 40 pg/mL. Methods Patients were randomized 1:1 to receive standard of care (SOC) or SOC plus one dose of tocilizumab. The primary outcome was death or need for invasive mechanical ventilation (IMV) within 28 days after randomization. Secondary outcomes included ICU admission, days on IMV and hospital stay. A meta-analysis of clinical trials to evaluate the effect of tocilizumab on mortality and need of IMV in patients with COVID-19 pneumonia was performed. Results Sixty-two patients were included: 30 in the SOC arm and 32 in the standard-treatment plus tocilizumab arm. The primary outcome occurred in 12.9% in the tocilizumab arm and 32.3% in the SOC arm(p = 0.068). There was a trend towards fewer days on IMV (7.5 vs 19.5 days, p = 0.073) and a shorter hospital stay (4 vs 8 days, p = 0.134) in the tocilizumab group. No serious adverse events were reported. The meta-analysis revealed a RR for death or IMV of 0.83 (95% CI: 0.77–0.89) in patients receiving tocilizumab, compared to patients receiving SOC. Conclusion Tocilizumab could be effective to prevent death or IMV in patients with severe COVID-19 pneumonia and high IL-6 serum levels. Safety profile of tocilizumab does not arise major concern in patients with severe COVID19., Open Access Funding provided by Universitat Autonoma de Barcelona. This study received support of “Plataforma ISCIII de Soporte para la Investigación Clínica—SCReN (Spanish Clinical Research Network)” which is funded by ISCIII through the project sPT17/0017/0030 and PT20/00078, which are both integrated in the “Plan Estatal de I + D + I 2013–2016 y 2017–2020” and co-funded by the “ Fondo Europeo de Desarrollo Regional (FEDER) “Una manera de hacer Europa””. ASM was supported by the Instituto de Salud Carlos III (Juan Rodés postdoctoral fellowship grant number JR18/00022) during the study period. JSN and JEP are supported by the Instituto de Salud Carlos III (Rio Hortega predoctoral grant numbers CM22/00262 and CM22/00246).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Alterations of the IKZF1-IKZF2 tandem in immune cells of schizophrenia patients regulate associated phenotypes

  • Ballasch, Iván
  • López-Molina, Laura
  • Galán-Ganga, Marcos
  • Sancho-Balsells, Anna
  • Rodríguez-Navarro, Irene
  • Borràs-Pernas, Sara
  • Rabadán, M. Ángeles
  • Chen, Wanqi
  • Pastó-Pellicer, Carlota
  • Flotta, Francesca
  • Maoyu, Wang
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
  • Aguilar, Ruth
  • Dobaño, Carlota
  • Egri, Natalia
  • Hernández, Carla
  • Alfonso, Miqueu
  • Juan, Manel
  • Alberch, Jordi
  • Toro, Daniel del
  • Arranz, Belén
  • Canals, Josep M.
  • Giralt, Albert
Schizophrenia is a complex multifactorial disorder and increasing evidence suggests the involvement of immune dysregulations in its pathogenesis. We observed that IKZF1 and IKZF2, classic immune-related transcription factors (TFs), were both downregulated in patients' peripheral blood mononuclear cells (PBMCs) but not in their brain. We generated a new mutant mouse model with a reduction in Ikzf1 and Ikzf2 to study the impact of those changes. Such mice developed deficits in the three dimensions (positive-negative-cognitive) of schizophrenia-like phenotypes associated with alterations in structural synaptic plasticity. We then studied the secretomes of cultured PBMCs obtained from patients and identified potentially secreted molecules, which depended on IKZF1 and IKZF2 mRNA levels, and that in turn have an impact on neural synchrony, structural synaptic plasticity and schizophrenia-like symptoms in in vivo and in vitro models. Our results point out that IKZF1-IKZF2-dependent immune signals negatively impact on essential neural circuits involved in schizophrenia., This work was supported by grants from Ministerio de Ciencia e Innovación/AEI/https://doi.org/10.13039/501100011033/ and “FEDER” to A.G.: PID2021-122258OB-I00 and to J.A.: PID2020-119386RB-100 and from Instituto de Salud Carlos III (ISCIII): PI17/00246 to B.A. Our technician Ana López, was supported by a María de Maeztu Unit of Excellence (Institute of Neurosciences, University of Barcelona, CEX2021-001159-M, Ministry of Science and Innovation). The project that gave rise to these results received the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is LCF/BQ/DR21/11880016 to M.G.-G.